Nano-formulations: Recent Trends for Ocular Bioavailability Enhancement
Abstract
Eye is a critical part of the body that is readily available and with damage having direct effects on the life of an individual. Delivery of ocular drugs always remain challenging for healthcare professionals and scientists all over the world due to the challenges that dynamic opthalamic environment provides. These challenges involves different barriers like corneal epithelium, corneal stroma, sclera and other bio-membranes (static barriers), choroidal or conjunctival blood flow, lymphatic clearance, tear turnover (dynamic barriers) and efflux pumps/enzymes(metabolic barriers).Ocular diseases include various diseases affecting different parts of the eye. The eye presents comprehensive perspectives and difficulties in the distribution of medicaments, primarily due to the exceptional ability inherent in this mechanism for drugs to enter the main circulatory system and also for eye barrier limitations. Even if conventional non-invasive and invasive treatments like eye drops, injectable preparations and implantable devices are available but these treatments either have bioavailability issues or serious adverse eye effects. Additionally, the new concept of nanoscience and nano-technology gives new a pathway for treating ocular disease. Different active molecules were engineered to communicate with nano-carriers to pass these eye barriers and interact closely with unique specific eye tissues. This study highlights the latest advances in nano-formulations for ophthalmic diagnosis and provides discussions in the mainstream of opthalamic diseases about the role of nano-formulations in nearby future.
Keywords: ocular diseases, nano-technology, static barrier, dynamic barrier, nano-carriers, bioavailability.
Keywords:
ocular diseases, nano-technology, static barrier, dynamic barrier, nano-carriers, bioavailabilityDOI
https://doi.org/10.22270/jddt.v12i2-S.5301References
Pascolini D, Mariotti SP, "Global estimates of visual impairment: 2010" Br. J. Ophthalmol, 2012; 96:614-618. https://doi.org/10.1136/bjophthalmol-2011-300539
Haupt C, Huber AB, "How axons see their way-axonal guidance in the visual system" Front. Biosci, 2008; 13:3136-3149. https://doi.org/10.2741/2915
Khutoryanskiy VV. Mucoadhesive Materials and Drug Delivery Systems. 1st edition. John Wiley & Sons, Ltd.: Chichester, UK; 2014. 39-60. https://doi.org/10.1002/9781118794203
Guerrero VA, Osuna IB, Pastoriza P, Martinez M, Vanrell RH, "Novel technologies for the delivery of ocular therapeutics in glaucoma" J. Drug Deliv. Sci. Technol, 2017; 42:181-192. https://doi.org/10.1016/j.jddst.2017.07.001
Todd TW, Beecher H, Williams GH, Todd AW, "The weight and growth of the human eye ball" Hum Biol, 1940; 12:1-20.
Willoughby CE, Ponzin D, Ferrari S, Lobo A, Landau K, Omidi Y, "Anatomy and physiology of the human eye: Effects of mucopolysaccharidoses disease on structure and function- A review" Clin. Exp. Ophthalmol, 2010; 38:2-11. https://doi.org/10.1111/j.1442-9071.2010.02363.x
Cholkar K, Dasari SR, Pal D, Mitra AK. Eye: Anatomy, physiology and barriers to drug delivery" In: Mitra, AK, editor. Ocular Transporters and Receptors. Woodhead Publishing Limited: Cambridge, UK; 2013:1-36. https://doi.org/10.1533/9781908818317.1
Gaudana R, Ananthula HK, Parenky A, Mitra AK, "Ocular Drug Delivery" AAPS J, 2010; 12:348-360. https://doi.org/10.1208/s12248-010-9183-3
Yi X, Wang Y, Yu FS, "Corneal epithelial tight junctions and their response to lipo-polysaccharide challenge" Invest Ophthalmol Vis Sci, 2000; 41(13):4093-100.
Cunha-Vaz J, "The blood-ocular barriers" Surv Ophthalmol, 1979; 23:279-296. https://doi.org/10.1016/0039-6257(79)90158-9
Furuichi M, Chiba T, Abe K, Kogure S , Iijima H, Tsukahara S et al, "Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier" J Glaucoma, 2001;10:233-236.
https://doi.org/10.1097/00061198-200106000-00016
Cunha-Vaz JG, "The blood-ocular barriers: past, present, and future" Doc Ophthalmol, 1997; 93:149-157. https://doi.org/10.1007/BF02569055
Gipson IK, Argueso P, "Role of mucins in the function of the corneal and conjunctival epithelia" Int Rev Cytol, 2003; 231:1-49. https://doi.org/10.1016/S0074-7696(03)31001-0
Gaudana R, Jwala, Boddu SH, Mitra AK, "Recent perspectives in ocular drug delivery" Pharm Res, 2009; 26:197-216. https://doi.org/10.1007/s11095-008-9694-0
Barar J, Javadzadeh AR, Omidi Y, "Ocular novel drug delivery: impacts of membranes and barriers" Expert Opin Drug Del, 2008; 5:567-581. https://doi.org/10.1517/17425247.5.5.567
Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG, "Topical and systemic drug delivery to the posterior segments" Adv Drug Deliv Rev, 2005; 57(14):2010-2032 https://doi.org/10.1016/j.addr.2005.09.004
Tatham AJ, Sarodia U, Gatrad F, Awan A, "Eye drop instillation technique in patients with glaucoma" Eye, 2013; 27:1293. https://doi.org/10.1038/eye.2013.187
Tiwari R, Pandey V, Asati S, Soni V, Jain D, "Therapeutic challenges in ocular delivery of lipid based emulsion" Egypt. J. Basic Appl. Sci, 2018; 5:121-129. https://doi.org/10.1016/j.ejbas.2018.04.001
Peng CC, Bengani LC, Jung HJ, Leclerc J, Gupta C, Chauhan A, "Emulsions and microemulsions for ocular drug delivery" J. Drug Deliv. Sci. Technol, 2011; 21:111-121. https://doi.org/10.1016/S1773-2247(11)50010-3
Tamilvanan S, Benita S, "The potential of lipid emulsion for ocular delivery of lipophilic drugs" Eur. J. Pharm. Biopharm, 2004; 58:357-368. https://doi.org/10.1016/j.ejpb.2004.03.033
Opitz DL, Harthan JS, "Review of Azithromycin Ophthalmic 1% Solution (AzaSite) for the Treatment of Ocular Infections" Ophthalmol. Eye Dis, 2012; 4:1-14. https://doi.org/10.4137/OED.S7791
Ousler GW, Michaelson C, Christensen MT, "An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops" Cornea, 2007; 26:949-952. https://doi.org/10.1097/ICO.0b013e3180de1c38
Ursea R, Purcell TL, Tan BU, Nalgirkar A, Lovaton ME, Ehrenhaus MR, Schanzlin DJ, "The effect of cyclosporine A (Restasis) on recovery of visual acuity following LASIK" J. Refract. Surg, 2008; 24:473-476. https://doi.org/10.3928/1081597X-20080501-04
Dubald M, Bourgeois S, Andrieu V, Fessi H, "Ophthalmic Drug Delivery Systems for Antibiotherapy- A Review" Pharmaceutics, 2018; 10(1):10. https://doi.org/10.3390/pharmaceutics10010010
Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS, "Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb" J. Drug Deliv, 2012; 604:204. https://doi.org/10.1155/2012/604204
Robin JS, Ellis PP, "Ophthalmic ointments" Surv. Ophthalmol, 1978; 22:335-340. https://doi.org/10.1016/0039-6257(78)90178-9
Scruggs J, Wallace T, Hanna C, "Route of absorption of drug and ointment after application to the eye" Ann. Ophthalmol, 1978; 10:267-271.
MacKeen DL, "Aqueous formulations and ointments" Int. Ophthalmol. Clin, 1980; 20:79-92. https://doi.org/10.1097/00004397-198002030-00009
Polin RA, Ditmar MF. Infectious Diseases. In: Pediatric Secrets. 5th ed. Mosby: Philadelphia, PA, USA; 2011:354-422. https://doi.org/10.1016/B978-0-323-06561-0.00011-2
Yasueda S, Inada K, Matsuhisa K, Terayama H, Ohtori A, "Evaluation of ophthalmic suspensions using surface tension" Eur. J. Pharm. Biopharm, 2004; 57:377-382. https://doi.org/10.1016/S0939-6411(03)00159-0
Edman P, "Pharmaceutical formulations-Suspensions and solutions" J. Aerosol. Med, 1994; 7:53-56. https://doi.org/10.1089/jam.1994.7.Suppl_1.S-3
Scoper SV, Kabat AG, Owen GR, Stroman DW, Kabra BP, Faulkner R, Kulshreshtha AK et al, "Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension" Adv. Ther, 2008; 25:77-88. https://doi.org/10.1007/s12325-008-0019-9
Ahmed I. The non-corneal route in ocular drug delivery. In: Mitra AK, editor. Ophthalmic drug delivery systems. 2nd ed, NewYork: Marcel Dekker; 2003: 335-363. https://doi.org/10.1201/9780203912072.ch11
Ward AH, Siegwart JT, Frost MR, Norton TT, "The effect of intravitreal injection of vehicle solutions on form deprivation myopia in tree shrews" Exp Eye Res, 2016; 145:289-296. https://doi.org/10.1016/j.exer.2016.01.015
Rivers HM, Ray CS, Shah JC, Mittal S, "A new vision for the eye: Unmet ocular drug delivery needs" Pharm Res, 2015; 32:2814-2823. https://doi.org/10.1007/s11095-015-1717-z
Urtti A, "Challenges and obstacles of ocular pharmacokinetics and drug delivery" Adv Drug Deliv Rev, 2006; 58:1131-1135. https://doi.org/10.1016/j.addr.2006.07.027
Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ, et al, "Diffusion of high molecular weight compounds through sclera" Invest Ophthalmol Vis Sci, 2000; 41:1181-1185.
Occhiutto ML, Freitas FR, Maranhao RC, Costa VP, "Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems" Pharmaceutics, 2012; 4:252-275. https://doi.org/10.3390/pharmaceutics4020252
Adibi SA, "Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance" Am J Physiol, 1997; 272:E723-736. https://doi.org/10.1152/ajpendo.1997.272.5.E723
Anand BS, Mitra AK, "Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea" Pharm Res, 2002; 19:1194-1202. https://doi.org/10.1023/A:1019806411610
Ocheltree SM, Keep RF, Shen H, Yang D, Hughes BA, Smith DE, "A preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes" Pharm Res, 2003; 20:1364-1372. https://doi.org/10.1023/A:1025741723724
Atluri H, Anand BS, Patel J, Mitra AK, "Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration" Exp Eye Res, 2004; 78:815-822. https://doi.org/10.1016/j.exer.2003.10.020
Dias C, Nashed Y, Atluri H, Mitra A, "Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and valval acyclovir following systemic administration in rabbits: an evaluation using ocular microdialysis and LC-MS" Curr Eye Res, 2002; 25:243-252. https://doi.org/10.1076/ceyr.25.4.243.13488
Winkler BS, "Glycolytic and oxidative metabolism in relation to retinal function" J Gen Physiol, 1981; 77:667-692. https://doi.org/10.1085/jgp.77.6.667
Ammar HO, Salama HA, Ghorab M, Mahmoud AA, "Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride" AAPS Pharm SciTech, 2009; 10:808-819. https://doi.org/10.1208/s12249-009-9268-4
Merriman-Smith R, Donaldson P, Kistler J, "Differential expression of facilitative glucose transporters GLUT1 and GLUT3 in the lens" Invest Ophthalmol Visual Sci, 1999; 40:3224-3230.
Mantych GJ, Hageman GS, Devaskar SU, "Characterization of glucose transporter isoforms in the adult and developing a human eye" Endocrinology, 1993; 133:600-607. https://doi.org/10.1210/endo.133.2.8344201
Brubaker RF, Bourne WM, Bachman LA, McLaren JW, "Ascorbic acid content of human corneal epithelium" Invest Ophthalmol Visual Sci, 2000; 41:1681-1683.
Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK, "Polymeric nanoparticulate system: A potential approach for ocular drug delivery" J Control Release, 2009; 136(1):2-13 https://doi.org/10.1016/j.jconrel.2008.12.018
Tong Y, Chang S, Liu C, Kao WW, Huang CH, Liaw J, "Eye drop delivery of nanopolymeric micelle formulated genes with cornea-specific promoters" J Gene Med, 2007; 9(11):956-966 https://doi.org/10.1002/jgm.1093
Wadhwa S, Paliwal R, Paliwal SR, Vyas SP, "Nanocarriers in ocular drug delivery: An update review" Curr Pharm Des, 2009; 15(23):2724-2750 https://doi.org/10.2174/138161209788923886
Zarbin MA, Montemagno C, Leary JF, Ritch R, "Nanomedicine in ophthalmology: The new frontier" Am J Ophthalmol, 2010; 150(2):144-162. https://doi.org/10.1016/j.ajo.2010.03.019
Ciolino JB, Hoare TR, Iwata NG, Behlau I, Dohlman CH, Langer R, Kohane DS, "A drug-eluting contact lens" Invest Ophthalmol Vis Sci, 2009; 50(7):3346-3352. https://doi.org/10.1167/iovs.08-2826
Gulsen D, Chauhan A, "Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle" Int J Pharm, 2005; 292(1-2):95-117. https://doi.org/10.1016/j.ijpharm.2004.11.033
Gulsen D, Li CC, Chauhan A, "Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery" Curr Eye Res, 2005; 30(12):1071-1080 https://doi.org/10.1080/02713680500346633
Jimenez N, Galan J, Vallet A, Egea MA, Garcia ML, "Methyl trypsin loaded poly( D, L-lactide- coglycolide) nanoparticles for contact lens care" J Pharm Sci, 2010; 99(3):1414-1426 https://doi.org/10.1002/jps.21937
Kapoor Y, Chauhan A, "Drug and surfactant transport in Cyclosporine A and Brij 98 laden p-HEMA hydrogels" J Colloid Interface Sci, 2008; 322(2) 624-633. https://doi.org/10.1016/j.jcis.2008.02.028
Phan CM, Subbaraman L, Liu S, Gu F, Jones L, "In vitro uptake and release of natamycin Dex-b-PLA nanoparticles from model contact lens materials" J Biomater Sci Polym, 2014; 25(1):18-31. https://doi.org/10.1080/09205063.2013.830914
Li X, Zhang Z, Chen H, "Development and evaluation of fast forming nano-composite hydrogel for ocular delivery of diclofenac" Int J Pharm, 2013; 448(1):96-100. https://doi.org/10.1016/j.ijpharm.2013.03.024
Vandamme TF, Brobeck L, "Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide" J. Controll. Release, 2005; 102:23-38. https://doi.org/10.1016/j.jconrel.2004.09.015
Yavuz B, Pehlivan SB, Unlu N, "Dendrimeric Systems and Their Applications in Ocular Drug Delivery" The Scientific World Journal, 2013. https://doi.org/10.1155/2013/732340
Ansari MJ, Kohli K, Dixit N, "Microemulsions as potential drug delivery systems: a review" PDA J Pharm Sci Technol, 2008; 62(1):66-79.
Vandamme TF, "Microemulsions as ocular drug delivery systems: recent developments and future challenges" Prog Retinal Eye Res, 2002; 21(1):15-34. https://doi.org/10.1016/S1350-9462(01)00017-9
Hasse A, Keipert S, "Development and characterization of microemulsions for ocular application" Eur J Pharm Biopharm, 1997; 43:179-183. https://doi.org/10.1016/S0939-6411(96)00036-7
Chan J, Maghraby GM, Craig JP, Alany RG, "Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation" Int J Pharm, 2007; 328:65-71. https://doi.org/10.1016/j.ijpharm.2006.10.004
Vega E, Egea MA, Valls O, Espina M, Garcia ML, "Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration" J. Pharm. Sci, 2006; 95:2393-2405. https://doi.org/10.1002/jps.20685
Sai HSB, "Polymeric nanoparticles for ophthalmic drug delivery: an update on research and patenting activity" Recent Pat. Nanomed, 2012; 2:96-112. https://doi.org/10.2174/1877912311202020096
Gaven UM, Yenilmez E, "Olopatadine hydrochloride loaded Kollidon® SR nanoparticles for ocular delivery: nanosuspension formulation and in vitro-in vivo evaluation" J. Drug Deliv. Sci. Technol, 2019; 51:506-512. https://doi.org/10.1016/j.jddst.2019.03.016
Swati V, Pratik K, Manasi C, John D, Vandana P, "Multidimensional ophthalmic nanosystems for molecular detection and therapy of eye disorders" Curr. Pharmaceut. Des, 2015; 21:3223-3238. https://doi.org/10.2174/1381612821666150531171052
Yellepeddi VK, Palakurthi S, "Recent advances in topical ocular drug delivery" J. Ocul. Pharmacol. Ther, 2016; 32:67-82. https://doi.org/10.1089/jop.2015.0047
Jwala J, Boddu SHS, Shah S, Sirimulla S, Pal D, Mitra AK, "Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir" J. Ocul. Pharmacol. Ther, 2011; 27:163-172. https://doi.org/10.1089/jop.2010.0188
De Campos AM, Sanchez A, Gref R, Calvo P, Alonso MJ, "The effect of a PEG versus a chitosan coating on the interaction of colloidal drug carriers with the ocular mucosa" Eur J Pharm Sci, 2003; 20:73-81. https://doi.org/10.1016/S0928-0987(03)00178-7
Gaucher G, Marchessault RH, Leroux J, "Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes" J Control Release, 2010; 143(1):2-12 https://doi.org/10.1016/j.jconrel.2009.11.012
Cho HK, Cheong IW, Lee JM, Kim JH, "Polymeric nanoparticles, micelles and polymersomes from amphiphilic block copolymer" Korean J Chem Eng, 2010; 27(3):731-740 https://doi.org/10.1007/s11814-010-0216-5
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE, "Biodegradable polymeric nanoparticles as drug delivery devices" J Control Release, 2001; 70(1-2):1-20. https://doi.org/10.1016/S0168-3659(00)00339-4
Peniche H, Peniche C, "Chitosan nanoparticles: a contribution to nanomedicine" Polym Int 2011; 60(6):883-889. https://doi.org/10.1002/pi.3056
El-Kamel AH, "In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate" Int J Pharm, 2002; 241(1):47-55 https://doi.org/10.1016/S0378-5173(02)00234-X
Ma W, Xu H, Wang C, Nie S, Pan W, "Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system" Int J Pharm, 2008; 350(1-2):247-256. https://doi.org/10.1016/j.ijpharm.2007.09.005
Kaur IP, Garg A, Singla AK, Aggarwal D, "Vesicular systems in ocular drug delivery: an overview" Int. J. Pharm, 2004; 269: 1-14. https://doi.org/10.1016/j.ijpharm.2003.09.016
Shen Y, Tu J, "Preparation and ocular pharmacokinetics of ganciclovir liposomes" AAPS J, 2007; 9:E371-E377. https://doi.org/10.1208/aapsj0903044
Chauhan P, Tyagi BK, Herbal novel drug delivery systems and transfersomes, Journal of Drug Delivery and Therapeutics 2018; 8(3):162-168. https://doi.org/10.22270/jddt.v8i3.1772
Fresta M, Panico AM, Bucolo C, Giannavola C, Puglisi G, "Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir" J. Pharm. Pharmacol, 1999; 51:565-576. https://doi.org/10.1211/0022357991772664
Published
Abstract Display: 588 
PDF Downloads: 660 PDF Downloads: 44 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.